Abstract
The peroxisome proliferator-activated receptors (PPARs) have increasingly become attractive targets for developing novel anti-type 2 diabetic drugs. We employed comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) to study three-dimensional quantitative structure–activity relationship (3D QSAR) based on existing agonists of PPARγ (including five thiazolidinediones and 74 tyrosine-based compounds). Predictive 3D QSAR models with conventional r 2 and cross-validated coefficient (q 2) values up to 0.974 and 0.642 for CoMFA and 0.979 and 0.686 for COMSIA were established using the SYBYL package. These models were validated by a test set containing 18 compounds. The CoMFA and CoMSIA field distributions are in general agreement with the structural characteristics of the binding pockets of PPARγ, which demonstrates that the 3D QSAR models built here are very useful in predicting activities of novel compounds for activating PPARγ.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kersten S, Desvergne B, Wahli W (2000) Nature 405:421–424
Willson TM, Brown PJ, Sternbach DD, Henke BR (2000) J Med Chem 43:527–550
Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA (1995) J Biol Chem 270:12953–12956
Issemann I, Green S (1990) Nature 347:645–650
Wang YX, Lee CH, Tiep SR, Yu T, Ham J, Kang H, Evans RM (2003) Cell 113:159-170
Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R, Rosenfeld MG, Willson TM, Glass CK, Milburn MV (1998) Nature 395:137–143
Uppenberg J, Svensson C, Jaki M, Bertilsson G, Jendeberg L, Berkenstam A (1998) J Biol Chem 273:31108–31112
Xu HE, Lambert MH, Montana VG, Plunket GM, Moore LB, Collins JL, Oplinger JA, Kliewer SA, Gampe RT, McKee DD, Moore JT, Willson TM (2001) PNAS 98:13919–13924
Henke BR, Blanchard SG, Brackeen MF, Brown KK, Cobb JE, Collins JL, Harrington WW, Hashim MA, Hull-Ryde EA, Kaldor I, Kliewer SA, Lake DH, Leesnitzer LM, Lehmann JM, Lenhard JM, Orband-Miller LA, Miller JF, Mook RA, Noble SA, Oliver W, Parks DJ, Plunket KD, Szewczyk JR, Willson TM (1998) J Med Chem 41:5020–5036
Collins JL, Blanchard SG, Boswell GE, Charifson PS, Cobb JE, Henke BR, Hull-Ryde EA, Kazmierski WM, Lake DH, Leesnitzer LM, Lehmann J, Lenhard JM, Orband-Miller LA, Gray-Nunez Y, Parks DJ, Plunkett KD, Tong WQ (1998) J Med Chem 41:5037–5054
Cobb JE, Blanchard SG, Boswell EG, Brown KK, Charifson PS, Cooper JP, Collins JL, Dezube M, Henke BR, Hull-Ryde EA, Lake DH, Lenhard JM, Oliver W, Oplinger J, Pentti M, Parks DJ, Plunker KD, Tong WL (1998) J Med Chem 41:5055–5069
Henke BR, Adkison KK, Blanchard SG, Leesnitzer LM, Robert A, Mook J, Plunket DK, Ray JA, Roberson C, Unwalla R, Willson TM (1999) Bioorg Med Chem Lett 9:3329–3334
Buckle DR, Cantello BCC, Cawthorne MA, Coyle PJ, Dean DK, Faller A, Haigh D, Hindley RM, Jefcott LJ, Lister CA, Pinto IL, Rami HK, Smith DG, Smith SA (1996) Bioorg Med Chem Lett 6:2121–2126
Buckle DR, Cantello BCC, Cawthorne MA, Coyle PJ, Dean DK, Faller A, Haigh D, Hindley RM, Jefcott LJ, Lister CA, Pinto IL, Rami HK, Smith DG, Smith SA (1996) Bioorg Med Chem Lett 6:2127–2130
Shinkai H, Onogi S, Tanaka M, Shibata T, Wao M, Wakitani K, Uchida I (1998) J Med Chem 41:1927–1933
Sauerberg P, Pettersson I, Jeppesen L, Bury PS, Mogensen JP, Wassermann K, Brand CL, Sturis J, Woldike HF, Fleckner J, Andersen AST, Mortensen SB, Svensson LA, Rasmussen HB, Lehmann SV, Polivka Z, Sindelar K, Panajotova V, Ynddal L, Wulff EM (2002) J Med Chem 45:789–804
Cramer RD, Patterson DE, Bunce JD (1988) J Am Chem Soc 110:5959–5967
Klebe G, Abraham U, Mietzner T (1994) J Med Chem 37:4130–4146
Klebe G (1998) Perspect Drug Discovery Des 12:87–104
Böhm M, Stürzebecher J, Klebe G (1999) J Med Chem 42:458–477
Kurogi Y (1999) Drug Des Discov 16:109–118
Kulkarni SS, Gediya LK, Kulkarni VM (1999) Bioorgan Med Chem 7:1475–1485
SYBYL 681 (2001) Tripos Inc, 1699 Hanley Road, St Louis, MO 63144, USA
Parks DJ, Tomkinson NCO, Villeneuve MS, Blanchard SG, Willson TM (1998) Bioorg Med Chem Lett 8:3657–3658
Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE (2000) Nucleic Acids Res 28:235–242
Gampe Jr RT, Montana VG, Lambert MH, Miller AB, Bledsoe RK, Milburn MV, Kliewer SA, Willson TM, Xu HE (2000) Mol Cell 5:545–555
Clark M, Cramer RD, van Opdenbosh N (1989) J Comput Chem 10:982–1012
Stewart JJ (1990) J Comput-Aided Mol Des 4:1–105
Kearsley SK, Smith GM (1990) Tetrahedron Comput Methodol 3:615–633
Weatherman RV, Fletterick RJ, Scanlan TS (1999) Annu Rev Biochem 68:559–581
Xu HE, Lambert MH, Montana VG, Plunket GM, Moore LB, Collins JL, Oplinger JA, Kliewer SA, Gampe RT, McKee DD, Moore JT, Willson TM (2001) PNAS 98:13919–13924
Grossman SL, Lessem L (1997) Exp Opin Ivest Drugs 6:1025–1040
Henry RR (1997) Endocrinol Metab Clin North Am 26:553–573
Acknowledgements
The authors gratefully acknowledge financial supports from the national “863” project of People’s Republic of China and project of “Most Important Biopharmaceutical Projects” by Guangdong province government in China. The authors also want to give special thanks to Drs Zhiqiang Ning and Weiming Hu for their support of this project.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Liao, C., Xie, A., Zhou, J. et al. 3D QSAR studies on peroxisome proliferator-activated receptor γ agonists using CoMFA and CoMSIA. J Mol Model 10, 165–177 (2004). https://doi.org/10.1007/s00894-003-0175-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00894-003-0175-4